Global Iron Deficiency Anemia Therapy Market Poised for Growth, Forecasted to Reach $4.6 Billion by 2030
February 01, 2024 10:05 ET
|
Research and Markets
Dublin, Feb. 01, 2024 (GLOBE NEWSWIRE) -- The "Iron Deficiency Anemia Therapy Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's...
Global Iron Deficiency Anemia Therapy Market Analysis 2024-2034 Featuring Profiles of Leading Players Including AbbVie, Bayer, CSL Vifor, Sanofi, and Teoxane
January 24, 2024 14:20 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Iron Deficiency Anemia Therapy Market Analysis & Forecast 2024-2034" report has been added to ResearchAndMarkets.com's offering. The...
FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting
December 09, 2023 17:02 ET
|
FibroGen, Inc.
please call Meichiel Keenan@650-219-6482 with any questions.
FibroGen/Astellas’ EVRENZO (roxadustat) Making In-Roads in European Market as In-Class Challenger, Akebia/Medice’s VAFSEO (vadadustat), Prepares for Launch in Early 2024.
December 08, 2023 09:10 ET
|
Spherix Global Insights
Exton, Pennsylvania, Dec. 08, 2023 (GLOBE NEWSWIRE) -- EVRENZO made history as the initial hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) to receive EU approval in August 2021,...
Global Hematology Collaboration and Licensing Agreements Analysis Report 2023: In-depth Understanding of Hematology Trends and Structure of Deals by Leading Biopharma Companies
November 16, 2023 07:18 ET
|
Research and Markets
Dublin, Nov. 16, 2023 (GLOBE NEWSWIRE) -- The "Hematology Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.Hematology Collaboration and...
Global Chemotherapy-Induced Anemia Market Forecast to 2027: Projections for RBC (Red Blood Cells) Transfusion, Erythropoiesis-Stimulating Agents (ESAs), and Iron Supplementation Treatments
November 01, 2023 08:33 ET
|
Research and Markets
Dublin, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The "Global Chemotherapy-Induced Anemia Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global chemotherapy-induced...
FibroGen to Report Third Quarter 2023 Financial Results
October 23, 2023 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2023 financial results on Monday, November 6 after the market close. FibroGen will also...
Sickle Cell Disease Treatment Market to hit USD 7.79 billion by 2032, says Global Market Insights Inc.
September 10, 2023 18:30 ET
|
Global Market Insights Inc.
Selbyville, Delaware, Sept. 10, 2023 (GLOBE NEWSWIRE) -- Sickle Cell Disease Treatment Market size is expected to be worth USD 7.79 billion by 2032. SCD is a genetic disorder that affects millions...
Global Sickle Cell Anemia Testing & Screening Market Forecast 2023-2030: Agios Pharmaceuticals, Bio-Rad, and Quest Diagnostics Among Key Players in Market
August 21, 2023 05:43 ET
|
Research and Markets
Dublin, Aug. 21, 2023 (GLOBE NEWSWIRE) -- The "Global Sickle Cell Anemia Testing & Screening Market by Technology, Age Group, Sector - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and...
Akebia’s Vafseo (vadadustat) Poised to Make Waves for GSK’s Jesduvroq and FibroGen/Astellas’ Evrenzo
July 20, 2023 15:07 ET
|
Spherix Global Insights
Exton, Pennsylvania, July 20, 2023 (GLOBE NEWSWIRE) -- Nephrologists have long awaited the approval of HIF-PH inhibitors for the treatment of anemia in their chronic kidney disease (CKD) patients....